/ZEAL.CO

ZEAL.CO Stock - Zealand Pharma A/S

Q: What is the analyst price target for ZEAL.CO?

Analyst price target information is not currently available for ZEAL.CO.

Q: What is ZEAL.CO's market cap?

Market capitalization information is not currently available for ZEAL.CO.

Healthcare|Biotechnology|CPH

$483.00+1.60%

+$7.60 (+1.60%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $531.30

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ZEAL.CO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.55

52W High$808.00

52W Low$306.10

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$62.69M	$342.79M	$103.99M	$292.57M	$353.31M
Gross Profit	$54.82M	$323.61M	$73.28M	$173.75M	$262.75M
Gross Margin	87.4%	94.4%	70.5%	59.4%	74.4%
Operating Income	$-1,272,207,000	$-572,238,000	$-816,599,000	$-1,050,197,000	$-828,756,000
Net Income	$-1,078,828,000	$-703,739,000	$-965,610,000	$-1,018,149,000	$-846,729,000
Net Margin	-1720.9%	-205.3%	-928.6%	-348.0%	-239.7%
EPS	$-16.24	$-12.44	$-20.90	$-23.75	$-22.07

Company Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Visit Website

Earnings History & Surprises

ZEAL.CO

Beat Rate

39%

Last 18 quarters

Avg Surprise

-26.5%

EPS vs Estimate

Beats / Misses

7/11

Last 12 quarters

Latest EPS

$-5.80

Q4 2025

EPS Surprise History

Q1 24

-14.5%

$-4.41vs$-3.85

Q2 24

+11.7%

$-3.71vs$-4.20

Q3 24

-16.5%

$-4.67vs$-4.01

Q4 24

-6.2%

$-3.77vs$-3.55

Q1 25

+21.7%

$-4.12vs$-5.26

Q2 25

-642.2%

$-4.75vs$-0.64

Q3 25

-3.6%

$105.61vs$109.53

Q4 25

+27.9%

$-5.80vs$-8.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 19, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	$-8.04	$-5.80	+27.9%	✓ BEAT
Q3 2025	Aug 14, 2025	$109.53	$105.61	-3.6%	✗ MISS
Q2 2025	May 8, 2025	$-0.64	$-4.75	-642.2%	✗ MISS
Q1 2025	Feb 20, 2025	$-5.26	$-4.12	+21.7%	✓ BEAT
Q4 2024	Nov 7, 2024	$-3.55	$-3.77	-6.2%	✗ MISS
Q3 2024	Aug 15, 2024	$-4.01	$-4.67	-16.5%	✗ MISS
Q2 2024	May 16, 2024	$-4.20	$-3.71	+11.7%	✓ BEAT
Q1 2024	Feb 27, 2024	$-3.85	$-4.41	-14.5%	✗ MISS
Q4 2023	Nov 9, 2023	$-2.33	$1.23	+152.8%	✓ BEAT
Q3 2023	Aug 17, 2023	$-4.69	$-5.50	-17.3%	✗ MISS
Q2 2023	May 11, 2023	$-3.73	$-3.76	-0.8%	✗ MISS
Q1 2023	Mar 2, 2023	$-5.75	$-6.61	-15.0%	✗ MISS
Q4 2022	Nov 10, 2022	$-5.20	$-3.21	+38.3%	✓ BEAT
Q3 2022	Aug 11, 2022	$-7.56	$-11.04	-46.0%	✗ MISS
Q2 2022	May 13, 2022	$-6.62	$-5.16	+22.1%	✓ BEAT
Q1 2022	Mar 10, 2022	$-6.35	$-6.49	-2.2%	✗ MISS
Q4 2021	Nov 12, 2021	$-6.16	$-4.61	+25.2%	✓ BEAT
Q3 2021	Aug 12, 2021	$-6.15	$-6.87	-11.7%	✗ MISS